Kaempferol Inhibits the Primary Attachment Phase of Biofilm Formation in Staphylococcus aureus

The ability to form biofilms on surfaces makes the main pathogenic factor in implanted medical device infections. The aim of this study was to discover a biofilm inhibitor distinct from the antibiotics used to prevent infections resulting from biofilms. Here, we describe kaempferol, a small molecule...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 8; p. 2263
Main Authors Ming, Di, Wang, Dacheng, Cao, Fengjiao, Xiang, Hua, Mu, Dan, Cao, Junjie, Li, Bangbang, Zhong, Ling, Dong, Xiaoyun, Zhong, Xiaobo, Wang, Lin, Wang, Tiedong
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 15.11.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The ability to form biofilms on surfaces makes the main pathogenic factor in implanted medical device infections. The aim of this study was to discover a biofilm inhibitor distinct from the antibiotics used to prevent infections resulting from biofilms. Here, we describe kaempferol, a small molecule with anti-biofilm activity that specifically inhibited the formation of biofilms. Crystal violet (CV) staining and fluorescence microscopy clearly showed that 64 μg/ml kaempferol inhibited biofilm formation by 80%. Meanwhile, the minimum inhibitory concentration (MIC) and growth curve results indicated that kaempferol had no antibacterial activity against the tested bacterial strain. Kaempferol inhibited the primary attachment phase of biofilm formation, as determined by a fibrinogen-binding assay. Moreover, a fluorescence resonance energy transfer (FRET) assay and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analyses revealed that kaempferol reduced the activity of sortaseA (SrtA) and the expression of adhesion-related genes. Based on these results, kaempferol provides a starting point for the development of novel anti-biofilm drugs, which may decrease the risk of bacterial drug resistance, to prevent biofilm-related infections.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Emily E. Weinert, Emory University, United States; Fabian Davamani Amalraj, International Medical University, Malaysia; Sarah Rowe-Conlon, University of North Carolina at Chapel Hill, United States
Edited by: Yuji Morita, Aichi Gakuin University, Japan
These authors have contributed equally to this work.
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2017.02263